Document:

EX-4.1

 Exhibit 4.1 

REGISTRATION RIGHTS AGREEMENT 

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and made effective as of April 29, 2021, 2021 (the
“Effective Date”) by and between Hecla Mining Company, a Delaware corporation (“Hecla”), and Waterton Nevada Splitter, LLC, a Nevada limited liability company (“Waterton”). 

WHEREAS, on July 20, 2018, Hecla issued to Waterton 2,068,000 warrants to purchase shares of common stock of Hecla at the price of
U.S.$8.03 per share pursuant to that Warrant Certificate No. 2018-1 (such warrants, collectively, as the same may be amended from time to time, including any replacement warrants issued in respect
thereof, the “Warrants”); and 
 WHEREAS, concurrently with the execution and delivery of this Agreement, the parties are
entering into an amendment to Warrants to grant to the Holders (as defined below) the registration rights set forth in this Agreement in respect of the Registrable Securities (as defined below). 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

1.    Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings given to
such terms in the Warrants. The following terms shall have the following meanings for purposes of this Agreement: 

“Commission” means the United States Securities and Exchange Commission. 

“Exchange Act” means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. 
 “Holder” means each holder of the Warrants and/or any transferee that acquires all or any portion of the
Warrants from time to time and, if such holder or transferee has acquired any Registrable Securities, then Holder shall also be deemed to include the holder of such Registrable Securities, and “Holders” means all of such Persons
collectively. 
 “Majority-in-Interest
Holders” means Holders holding a majority of the Registrable Securities. 
 “Proceeding” means an action, claim,
suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. 

“Prospectus” means the prospectus included in the Registration Statement (including, without limitation, a prospectus that
includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the
terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference in
such Prospectus. 

 “Registrable Securities” means all the shares of common stock of Hecla
issued or issuable from time to time upon the exercise of the Warrants (and the shares of common stock actually issued in respect of such securities upon any stock splits, stock dividends, or similar transactions); provided, that any such securities
shall cease to constitute “Registrable Securities” (and Hecla shall not be required to maintain the effectiveness of any Registration Statement, or file any post-effective amendment, any prospectus supplement or another Registration
Statement hereunder with respect thereto) upon the earliest of (i) the date on which such securities are disposed of pursuant to the Registration Statement, (ii) the date on which such securities have been sold pursuant to Rule 144 on the
New York Stock Exchange, (iii) the date on which such securities cease to be outstanding and (iv) the expiration of the Registration Period. 

“Registration Period” means the period commencing on the date on which the initial Registration Statement becomes effective
under the Securities Act and ending on the earlier of (i) the date on which all of the Warrants have been exercised in full and all of the shares of common stock issued upon such exercise of all of the Warrants have been sold by the Holders
under the Registration Statement or pursuant to Rule 144 on the New York Stock Exchange, and (ii) the later of (A) the first (1st) anniversary of the date on which all of the shares of
common stock issuable upon the exercise of the Warrants have been issued by Hecla after all of the Warrants have been exercised in full (provided that Rule 144 is then available for the resale of any remaining shares of common stock without any hold
period requirement) or, if required, such later period as needed to ensure that Rule 144 is then available for the resale of such shares of common stock without any hold period requirement and without any other restriction thereunder and after all
of the restrictive legends have been removed from all book entry positions or certificates representing such shares of common stock, and (B) if the Warrants have not been exercised in full at or prior to the expiration of the Warrants, the
expiration of the term of the Warrants. 
 “Registration Statement” means any registration statement contemplated by this
Agreement, including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference in such
registration statement. 
 “Rule 144” means Rule 144 under the Securities Act. 

“Rule 405” means Rule 405 under the Securities Act. 

“Securities Act” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “WKSI” means a well-known seasoned issuer (as defined in Rule 405). 

Any reference herein to a Rule promulgated under the Securities Act or the Exchange Act shall mean a reference to such Rule as it may be
amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

  
 2 

 2.    Shelf Registration. 

a.    As promptly as reasonably practicable but in no event more than thirty (30) days after the Effective Date,
Hecla shall prepare and file with the Commission the Registration Statement, which shall be a “resale” automatic shelf registration statement (as defined in Rule 405) providing for the resale of all the Registrable Securities pursuant to
an offering to be made on a continuous basis under Rule 415 under the Securities Act, filed on Form S-3 pursuant to General Instruction I.D(1)(d) thereto (or, if Hecla is not a WKSI, a shelf Registration
Statement on Form S-3, or, if Form S-3 is not available for the registration of the resale of Registrable Securities, Form
S-1 or such other form of registration statement as is then available to Hecla for such registration and acceptable to the
Majority-in-Interest Holders). The Registration Statement shall identify Waterton as the initial Holder and/or, if Hecla is so instructed by Waterton in writing, the
Registration Statement shall identify as a Holder any transferee that acquires all or any portion of the Warrants from Waterton. The Registration Statement shall also cover such indeterminate number of additional shares of common stock resulting
from stock splits, stock dividends or similar transactions of and/or from the Registrable Securities. The Registration Statement shall (i) include only the Registrable Securities and (ii) not contemplate an underwritten offering of the
Registrable Securities. No Holder shall be named as an “underwriter” in any Registration Statement without such Holder’s prior written consent. 

b.    Hecla shall use its commercially reasonable efforts to cause the Registration Statement to become effective under
the Securities Act (i) upon filing, if Hecla is a WKSI, or (ii) as soon as reasonably practicable after the filing thereof (but in no event later than the thirtieth (30th) day following
the filing thereof, unless the Registration Statement is the subject of a review by the Commission or its staff in which case the 90th day after filing thereof), if Hecla is not a WKSI. Hecla
shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act, including by filing any necessary post-effective amendments and Prospectus supplements and by filing one or more
replacement or renewal Registration Statements upon the expiration of such Registration Statement, until the expiration of the Registration Period. Subject to Sections 2(e) and 3(c), each Holder shall be entitled, at any time and from time to time
when a Registration Statement is effective, to sell any or all of the Registrable Securities covered by such Registration Statement. 

c.    Hecla shall use its commercially reasonable efforts to remain a WKSI (and not to become an ineligible issuer (as
defined in Rule 405)) during the period in which a Registration Statement is effective. If, at any time, Hecla determines that it is not a WKSI, Hecla shall use its commercially reasonable efforts to (i) as applicable, post-effectively amend
the automatic shelf registration statement to a shelf Registration Statement on Form S-3 or file a new shelf Registration Statement on Form S-3 or, if such form is not
available, Form S-1, (ii) have such shelf Registration Statement declared effective by the Commission as promptly as practicable and (iii) keep such Registration Statement effective until the expiration
of the Registration Period. If, at any time, Hecla files a Registration Statement on Form S-3 and thereafter Hecla becomes ineligible to use
Form S-3 for secondary sales, Hecla shall use its commercially reasonable efforts to (i) file a Registration Statement on Form S-1 as promptly
as practicable to replace the Registration Statement on Form S-3, (ii) have such Registration Statement on Form S-1 declared effective by the Commission as

  
 3 

 
promptly as practicable and (iii) cause such Registration Statement on Form S-1 to remain effective until the expiration of the Registration Period
and be supplemented and amended to the extent necessary to ensure that such Registration Statement is available or, if not available, that another Registration Statement is available, for the resale of all the Registrable Securities held by the
Holders. Upon such date as Hecla becomes eligible to use Form S-3 for secondary sales, Hecla shall use its commercially reasonable efforts to (i) file a Registration Statement on Form S-3 as promptly as practicable to replace the applicable Registration Statement on Form S-1, (ii) have such shelf Registration Statement declared
effective by the Commission as promptly as practicable and (iii) cause such Registration Statement to remain effective until the expiration of the Registration Period and be supplemented and amended to the extent necessary to ensure that such
Registration Statement is available or, if not available, that another Registration Statement is available, for the resale of all the Registrable Securities thereunder held by the Holders. 

d.    If the number of shares available under any Registration Statement is insufficient to cover all of the Registrable
Securities required to be covered by such Registration Statement, Hecla shall amend such Registration Statement (if permissible) or file with the Commission a new Registration Statement (on the short form available therefor, if applicable), or both,
so as to cover all of the Registrable Securities not covered by the initial Registration Statement, in each case as soon as reasonably practicable, but in any event not later than fifteen (15) days after the necessity therefor arises. Hecla
shall use its commercially reasonable efforts to cause such amendment to such Registration Statement and/or such new Registration Statement (as the case may be) to become effective under the Securities Act (i) upon filing, if Hecla is a WKSI,
or (ii) as soon as reasonably practicable after the filing thereof (but in no event later than the thirtieth (30th) day following the filing thereof unless the Registration Statement is the
subject of a review by the Commission or its staff in which case the 90th day after filing thereof), if Hecla is not a WKSI. 

e.    Hecla may suspend the disposition of Registrable Securities by the Holders pursuant to any Registration Statement up
to two (2) times during any 365-day period, with any such suspension not to exceed thirty (30) days for each suspension, by providing notice to the Holders. Each Holder agrees to hold in confidence
the fact that it has received such notice and any communication related thereto; provided, that Hecla shall not give reasons for such suspension should such reasons constitute material non-public
information. 
 3.    Hecla’s Obligations. In connection with any Registration Statement and subject
to Section 2(e), Hecla shall: 
 a.    within a reasonable time prior to the filing of any Registration Statement,
any Prospectus, any amendment to any Registration Statement, any amendment or supplement to a Prospectus or any issuer free writing prospectus covering Registrable Securities, provide copies of such documents to the Holders and their respective
counsel, fairly consider such reasonable changes in any such documents prior to the filing thereof as the Holders or their counsel may request, and make Hecla’s representatives available for discussion of such documents as may be reasonably
requested by the Holders; 

  
 4 

 b.    use its commercially reasonable efforts to cause any Registration
Statement and the related Prospectus and any amendment or supplement thereto, as of the effective date of such Registration Statement, amendment or supplement and during the distribution of the registered Registrable Securities (x) to comply in
all material respects with the requirements of the Securities Act and (y) not to contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading; 
 c.    notify the Holders promptly, and, if requested by any Holder, confirm such advice in writing,
(i) when any Registration Statement has become effective and when any post-effective amendments and supplements thereto become effective if such Registration Statement or post-effective amendment is not automatically effective upon filing
pursuant to Rule 462 under the Securities Act, (ii) of the issuance by the Commission or any U.S. state securities authority of any stop order, injunction or other order or requirement suspending the effectiveness of any Registration Statement
or the initiation of any proceedings for that purpose, (iii) if Hecla receives any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any jurisdiction or the initiation of any proceeding
for such purpose, and (iv) of the happening of any event during the period any Registration Statement is effective as a result of which such Registration Statement or the related Prospectus contains any untrue statement of a material fact or
omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading; provided that the Holders, upon receiving written notice of an event described in clauses (ii) to (iv) of this
Section 3.c, shall discontinue (and direct any other Person making offers and sales of Registrable Securities on their behalf to discontinue) offers and sales of Registrable Securities pursuant to any Registration Statement (other than those
pursuant to a plan in effect prior to such event and that complies with Rule 10b5-1 under the Exchange Act) until it is advised in writing by Hecla that the use of the applicable Prospectus may be resumed and
is furnished with an amended or supplemented Prospectus; 
 d.    if requested by any Holder, promptly incorporate in a
prospectus supplement or post-effective amendment such information as such Holder reasonably requests to be included therein, including, without limitation, naming such Holder as a selling security holder and the number of Registrable Securities
being sold by such Holder, and Hecla shall make all required filings of such prospectus supplement or post-effective amendment as soon as reasonably practicable after being notified of the matters incorporated in such prospectus supplement or
post-effective amendment; 
 e.    furnish the Holders’ counsel with copies of any written correspondence with the
Commission or any state securities authority relating to the Registration Statement or Prospectus, and use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement at the
earliest possible time; 

  
 5 

 f.    use its commercially reasonable efforts to cause all Registrable
Securities (i) to be qualified for inclusion in or listed on The New York Stock Exchange or any securities exchange on which Hecla’s shares of common stock are then so qualified or listed if so requested by the Majority-in-Interest Holders and (ii) to be registered and qualified under such other securities or state “blue sky” laws of such jurisdictions as any Holder
shall reasonably request in writing, and do all other acts and things which may be reasonably necessary or advisable to enable such Holder to consummate the disposition of the Registrable Securities in such jurisdictions (including keeping such
registration or qualification in effect for so long as the applicable Registration Statement remains in effect), except that in no event shall Hecla be required to qualify to do business as a foreign corporation in any jurisdiction where it would
not, but for the requirements of this Section 3.f, be required to be so qualified, to subject itself to taxation in any such jurisdiction or to consent to general service of process in any such jurisdiction; 

g.    use its commercially reasonable efforts to comply with all applicable rules and regulations of the Commission,
including making available to its security holders an earnings statement covering at least 12 months which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act (or any similar provision then
in force); and 
 h.    hold in confidence and not make any disclosure of information concerning each Holder provided to
Hecla unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration
Statement, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction, (iv) such
information has been made generally available to the public other than by disclosure in violation of this Agreement or (v) such information has been furnished by the Holder to Hecla for inclusion in the Registration Statement pursuant to
Section 4 of this Agreement; Hecla shall, upon learning that disclosure of such information concerning a Holder is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt written notice to such
Holder and allow such Holder, at such Holder’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information. 

4.    Information from the Holders. Each Holder shall furnish to Hecla such information (i) regarding
itself, its ownership of Registrable Securities and its proposed distribution of such Registrable securities, in each case as is required to be included in any Registration Statement, and (ii) as Hecla may from time to time reasonably request
in writing. 
 5.    Registration Expenses. All fees and expenses incident to the performance of or
compliance with this Agreement by Hecla, except as and to the extent specified in this Section 5, shall be borne by Hecla whether or not the Registration Statement is filed or becomes effective and whether or not any Registrable Securities are
sold pursuant to the Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, and to the extent applicable (i) all registration and filing fees (including, without limitation, fees
and expenses (A) with respect to filings required to be made with each securities exchange or market 

  
 6 

 
on which Registrable Securities are required hereunder to be listed, if any, (B) with respect to filing fees required to be paid to the Financial Industry Regulatory Authority and
(C) in compliance with state securities or “blue sky” laws), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses if the printing of
prospectuses is requested by Hecla), (iii) messenger, telephone and delivery expenses, (iv) Securities Act liability insurance, if Hecla elects to purchase such insurance and (v) fees and expenses of all other Persons retained by Hecla in
connection with the consummation of the transactions contemplated by this Agreement, including, without limitation, Hecla’s independent public accountants. In addition, Hecla shall be responsible for all of its internal expenses incurred in
connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit, the
fees and expenses incurred in connection with the listing of the Registrable Securities on the New York Stock Exchange or, if the shares of common stock are not then listed on the New York Stock Exchange, on any other securities exchange on which
the shares of common stock are then listed. Hecla shall not be responsible for any brokers’ and dealers’ discounts and commissions, transfer taxes or other similar fees incurred by any Holder in connection with the sale of the Registrable
Securities. 
 6.    Indemnification 

a.    Indemnification by Hecla. Hecla shall, notwithstanding any termination of this Agreement, indemnify and hold
harmless the Holders, their respective officers, directors, managers, employees and affiliates, each Person that controls any Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the
officers, directors, managers and employees of each such controlling Person (collectively, the “Holders Indemnified Parties”), to the full extent permitted by applicable law, from and against any and all losses, claims, damages,
liabilities, costs (including, without limitation, reasonable costs of preparation and reasonable attorneys’ and reasonable expert witnesses’ fees) and expenses (collectively, “Losses”) (as determined by a court of
competent jurisdiction in a final judgment not subject to appeal or review), to which such Holders Indemnified Parties may become subject under the Securities Act or otherwise, arising out of or relating to any violation of securities laws or untrue
or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any
omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they
were made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding any Holder furnished in writing to Hecla by such Holder expressly for use therein. Hecla
shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which Hecla is aware in connection with the transactions contemplated by this Agreement. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of any Holder, the directors, managers and officers of any Holder, or controlling Person of any Holder, and shall survive the transfer of such securities held by any Holder. 

  
 7 

 b.    Indemnification by the Holders. Each Holder, severally and
not jointly with any other Holder, shall indemnify and hold harmless Hecla, its directors, managers, officers, affiliates and employees, each Person that controls Hecla (within the meaning of Section 15 of the Securities Act and Section 20
of the Exchange Act), and the directors, managers, officers, affiliates and employees of such controlling Person (collectively, the “Hecla Indemnified Parties”), to the full extent permitted by applicable law, from and against all
Losses (as determined by a court of competent jurisdiction in a final judgment not subject to appeal or review), to which the Hecla Indemnified Parties may become subject under the Securities Act or otherwise, arising solely out of or based solely
upon any untrue statement of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising solely out of or based solely upon any omission of a material fact
required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, to the extent, but
only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder to Hecla specifically for inclusion in the Registration Statement or such Prospectus. Notwithstanding anything to the
contrary contained herein, each Holder shall be liable under this Section 6.b for only that amount as does not exceed the net proceeds to such Holder as a result of the sale of Registrable Securities pursuant to such Registration Statement. No
Holder shall be liable for any Losses under this Section 6.b where such Holder furnished in writing to Hecla information expressly for use in, and within a reasonable period of time prior to the effectiveness of, the Registration Statement or
any amendments or supplements thereto which corrected or made not misleading information previously provided to Hecla. 

c.    Conduct of Indemnification Proceedings. 

i.    If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an
“Indemnified Party”), such Indemnified Party promptly shall notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall be entitled to assume the defense
thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to
give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is
not subject to appeal or further review) that such failure shall have materially adversely prejudiced the Indemnifying Party. 

ii.    An Indemnified Party shall have the right to employ a single separate counsel in any such Proceeding
and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party 

  
 8 

 
unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses; or (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding
and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party,
and such parties shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the
Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one
separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or
delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party and indemnity has been sought hereunder, unless
such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. 

iii.    All fees and expenses of the Indemnified Party (including reasonable fees and expenses incurred in
connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section 6) shall be paid to the Indemnified Party, as incurred, within thirty (30) days of written notice thereof to the
Indemnifying Party (provided, that the Indemnified Party shall reimburse all such fees and expenses to the extent it is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder). 

d.    Contribution. To the extent any indemnification is prohibited or limited by law, then each Indemnifying Party
shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that
resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set
forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided
for in this Section was available to such party in accordance with its terms. Notwithstanding the provisions of this Section 6, except in the case of fraud or willful 

  
 9 

 
misconduct as determined by a final, nonappealable judicial determination, no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net
proceeds actually received by such Holder from the applicable sale of the Registrable Securities subject to the claim exceeds the amount of any damages that such Holder has otherwise been required to pay, or would otherwise be required to pay under
Section 6.b, by reason of such untrue or alleged untrue statement or omission or alleged omission. 

e.    Survival. The agreements contained in this Section 6 shall survive the transfer of the Registrable
Securities by a Holder and sale of all of the Registrable Securities pursuant to any registration statement and shall remain in full force and effect, regardless of any investigation made by or on behalf of any the Holders Indemnified Parties. 

7.    Rule 144. With a view to making available to each Holder the benefits of Rule 144 or any other similar
rule or regulation of the Commission that may at any time permit the Holders to sell Hecla’s securities to the public without registration pursuant to Rule 144, provided that a Holder holds any Registrable Securities which are eligible for
resale under Rule 144 and such information is necessary in order for such Holder to sell such Registrable Securities pursuant to Rule 144, Hecla agrees to: (a) make and keep public information available, as those terms are understood and
defined in Rule 144; (b) file with the Commission in a timely manner all reports and other documents required of Hecla under the Securities Act and the Exchange Act so long as Hecla remains subject to such requirements and the filing of such reports
and other documents is required for the applicable provisions of Rule 144; and (c) furnish to such Holder, promptly upon request, (i) a written statement by Hecla that it has complied with the reporting requirements of Rule 144, the
Securities Act and the Exchange Act applicable to Hecla and (ii) a copy of the most recent annual or quarterly report of Hecla and such other reports and documents so filed by Hecla (unless such report is publicly available on the
Commission’s website). 
 8.    No Inconsistent Agreements. Hecla shall not enter into any such
agreement with respect to its securities that violates the rights granted to the Holders in this Agreement. 

9.    Remedies. In the event of a breach by Hecla or any Holder of their respective obligations under this
Agreement, the non-breaching party, in addition to being entitled to exercise all rights granted by law and under this Agreement, will be entitled to seek specific performance of its rights under this
Agreement. Hecla and the Holders acknowledge and agree that monetary damages may not provide adequate compensation for any losses incurred by reason of a breach by either of them of any provisions of this Agreement and each further agrees that, in
the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. 

10.    Amendments and Waivers. The provisions of this Agreement may not be amended, modified or supplemented
unless the same shall be in writing and signed by Hecla and the Majority-in-Interest Holders. Each provision in this Agreement may only be waived by written instrument
making specific reference to this Agreement signed by the party against whom enforcement of any such provision so waived is sought. The waiver by any party of a breach of any provision of this Agreement shall not operate or be construed as a further
or continuing 

  
 10 

 
waiver of such breach or as a waiver of any other or subsequent breach. No failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. 

11.    Successors and Assigns. 

a.    This Agreement shall be binding upon and inure to the benefit of Hecla and the Holders and their successors and
permitted assigns. Hecla shall not (except by merger) assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the
Majority-in-Interest Holders. All or any portion of any Holder’s rights under this Agreement shall be assignable by such Holder to any transferee of all or any
portion of such Holder’s Registrable Securities or Warrants, provided that such Holder delivers to Hecla a written instrument executed by such transferee pursuant to which such transferee agrees to be bound by the provisions of this Agreement
applicable to a Holder with respect to the Registrable Securities or Warrants that have been assigned to such transferee. 

b.    If Hecla engages in any Fundamental Transaction as a result of which the Warrants and/or the Registrable Securities
are converted, exchanged or become exercisable into securities of another Person (including, without limitation, any Successor Entity), then Hecla shall cause the issuer of such securities to promptly (and in any event prior to completion of the
Fundamental Transaction) enter into an agreement to provide to the Holders the same registration rights and such other rights and obligations provided by Hecla hereunder to the Holders upon consummation of such Fundamental Transaction. To the extent
that such issuer was bound by registration rights obligations that would conflict with any provisions of this Agreement, Hecla shall use its commercially reasonable efforts to modify any such “inherited” registration rights obligations so
as not to interfere in any material respects with the rights provided under this Agreement. 
 12.    Entire
Agreement. This Agreement, together with the Warrants, constitutes the entire agreement of the parties with respect to the registration rights contemplated hereby, and supersedes all prior agreements and undertakings, both written and oral,
among the parties or between any of them, with respect to the subject matter hereof. 
 13.    Governing Law;
Consent to Jurisdiction. This Agreement shall be governed by the laws of the State of New York, regardless of any principles of conflicts of laws. Each party irrevocably and unconditionally (a) submits to the exclusive jurisdiction of
the courts of the State of New York sitting in New York County (or, if the courts of the State of New York sitting in New York County decline to accept jurisdiction over a particular matter, the United States District Court for the Southern District
of New York), and any appellate court from any thereof, in any Proceeding arising out of or relating to this Agreement and (b) waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such
Proceeding in any such court. 

  
 11 

 14.    Waiver of Jury Trial. THE PARTIES IRREVOCABLY AND
UNCONDITIONALLY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.
ANY PARTY MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED FOR AGREEMENT AMONG THE PARTIES TO WAIVE TRIAL BY JURY AND THAT ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT
OR ANY TRANSACTION CONTEMPLATED HEREBY SHALL INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY. 

15.    Severability. If any provision of this Agreement is invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any party. Upon such determination that any provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible, provided that any such modification does not affect the economic or legal substance of this Agreement and the
transactions contemplated hereby in a manner adverse to any party. 
 16.    Counterparts. This Agreement
may be executed in one or more counterparts, and by the different parties in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same instrument. This
Agreement may be delivered by .pdf transmission. 
 [Signature page follows.] 

  
 12 

 IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be signed, all as
of the date first written above. 
  

			
	HECLA MINING COMPANY
		
	By:	 	/s/ David C. Sienko
	Name:	 	David C. Sienko
	Title:	 	Vice President and General Counsel
	
	WATERTON NEVADA SPLITTER, LLC
		
	By:	 	/s/ Isser Elishis
	Name:	 	Isser Elishis
	Title:	 	Manager

  
 [Signature Page to
Registration Rights Agreement]Exhibit 10.1

 

 

 

May 15, 2021

 

Sandra Rojas-Caro, MD

via email to srojascaro@icloud.com

 

Re: Offer Letter of Employment

 

Dear Dr. Rojas-Caro:

 

I am thrilled to confirm our
offer to you of full-time employment with NeuBase Therapeutics, Inc. (the “Company”) in the position of Chief
Medical Officer. Your effective start date will be on May 24, 2021. Your principal place of employment will be in the Boston, MA
area and you will visit the Company’s headquarters in Pittsburgh, PA as appropriate. The terms of our offer and the benefits currently
provided by the Company are as follows:

 

1.            Salary.
Your starting annual salary will be $425,000 per year, less payroll deductions and withholdings, payable in accordance with the Company’s
standard policies and procedures and will be subject to review from time to time in accordance with the Company’s policies. You
will be eligible for an annual performance bonus with a target amount equal to 40% of your base salary (the “Annual Bonus”),
provided you remain employed by the Company on the date bonuses are paid. The amount of the Annual Bonus will be determined by
the Company’s Board of Directors (the “Board”) in good faith based on the level of achievement of the Company’s
objectives established by the Board and your personal objectives established by the CEO with your input and presented to the Compensation
Committee of the Board. Except as otherwise provided in this Agreement, you are entitled to such Annual Bonus determined by the Board
if you are an active employee of the Company as of December 31 of the calendar year to which such Annual Bonus relates.

 

2.            Benefits.
You will be eligible to participate in regular health insurance and other employee benefit plans established by the Company for its employees
from time to time, subject to the terms and conditions of such plans. The Company reserves the right to change or otherwise modify, in
its sole discretion, such benefit plans. You will be eligible for twenty-one (21) days of paid time off each year. The Company currently
has nine (9) paid holidays each year. Paid time- off may be taken in accordance with applicable Company policies which may be modified
from time to time.

 

3.            Equity.
Subject to the approval of the Board, the Company will issue you a stock option to purchase 280,000 shares of Common Stock of the
Company (the “Award”). The Award shall vest in accordance with the following schedule: l/4thof the total shares shall
vest on the first anniversary of the effective date of your employment, and 1/36th of the remaining shares shall vest on a monthly
basis starting on the first anniversary of the effective date of your employment; provided that vesting shall only occur on a scheduled
vesting date if your employment has not terminated prior to such vesting date, inclusive. The Award shall be issued pursuant to Company’s 2019
Stock Incentive Plan (as amended, the “Plan”) and form of award agreement adopted by the Board for use thereunder (collectively,
the “Grant Documents”). In the event of the termination of your employment by the Company (or its successor) without
Cause or by you due to resignation for Good Reason, in either case within 12 months following a Change in Control (as defined
in the Plan), then, subject to your execution and delivery of a general release of all claims, which shall include a non- disparagement
provision, in a form to be provided by the Company (“Separation Agreement”), and such Separation Agreement becoming
irrevocably effective within 60 days of the termination of your employment, your then outstanding, unvested Award, if any, will
vest and be exercisable as to all of the covered shares. You should consult with your own tax advisor concerning the tax risks associated
with accepting the Award. Notwithstanding anything to the contrary contained in this Agreement, the Separation Agreement (i) shall
not contain any terms or conditions that lessen the rights and benefits to which you are entitled under this Agreement, the Grant Documents
or any additional Awards (as defined in the Plan) under the Plan or increase your obligations under the Confidentiality Agreement and
(ii) shall provide that the following claims are excluded from the general release of all claims set forth in the Separation Agreement:
(a) any claims or rights which cannot be waived by law, including your right to accrued and unused vacation pay; (b) any claims
for the payments and benefits due under this Agreement or claims to enforce rights that accrue under this Agreement following termination
of employment; (c) any claims or rights to any vested benefits or vested rights that you may have under any employee benefit, retirement,
pension or equity plans; (d) non- termination related claims under the Employee Retirement Income Security Act (29 U.S.C. §
1001 et seq.), as amended; (e) any rights and/or claims under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”)
to elect continued group health plan coverage; (f) claims for reimbursement of approved business expenses incurred prior to the termination
of employment; (g) rights, if any, to defense and indemnification from the Company or its insurers for actions taken by you in the
course and scope of Executive’s employment with the Company, including, without limitation, rights of defense and indemnification
under the Company’s Amended and Restated Bylaws, as a matter of law or under any directors and officers insurance policies or the
Company’s indemnification policy; (h) any right you may have at law to obtain contribution as permitted by law in the event
of entry of judgment against you as a result of any act or failure to act for which you and the Company or its past, present and future
trustees, officers, agents, administrators, representatives, employees, affiliates, or insurers are held jointly liable; or (i) any
rights and/or claims you may have as a shareholder of the Company.

 

    1

     

    

 

4.            Policies;
Confidentiality. As a Company employee, you will be expected to abide by Company rules, procedures and policies, as adopted or revised
from time to time, and acknowledge in writing that you have read the Company’s Employee Handbook. As an employee of the Company,
you will have access to certain confidential information of the Company and you may, during the period of time that you are an employee
of the Company, develop certain information or inventions that will be the property of the Company. To protect the interests of the Company,
you will need to sign the Company’s standard Proprietary Information and Inventions Assignment Agreement attached as Exhibit A
(the “Confidentiality Agreement”) as a condition of your employment. We wish to impress upon you that we do not want
you to, and we hereby direct you not to, bring with you any confidential or proprietary material of any former employer or to violate
any other obligations you may have to any former employer. During the period of time that you render services to the Company, you agree
not to engage in any employment, business, or activity that is in any way competitive with the business or proposed business of the Company
in the Competitive Field (“Compete”). You will disclose to the Company in writing any other gainful employment, business
or activity that you are currently associated with or participate in that Competes with the Company. During the period of time that you
are an employee of the Company, you will not assist any other person or organization in Competing with the Company or in preparing to
engage in competition with the business or proposed business of the Company. You represent that (i) this letter, (ii) the Confidentiality
Agreement, (iii) the Grant Documents and (iv) your commencement of employment with the Company, will not violate any agreement
currently in place between yourself and current or past employers.

 

    2

     

    

 

5.            At
Will Employment. While we look forward to a long and profitable relationship, should you decide to accept our offer, you will be an
at-will employee of the Company, which means your employment relationship with the Company can be terminated by either of you or the Company
for any reason, at any time, with or without prior notice and with or without cause. Any statements or representations to the contrary
(and, indeed, any statements contradicting any provision in this letter) should be regarded by you as ineffective. Further, your participation
in any equity or benefit plan or program is not to be regarded as assuring you of continuing employment for any particular period of time.
Any modification or change in your at will employment status may only occur by way of a written agreement signed by you and the Chief
Executive Officer of the Company. Should your employment be terminated by the Company without Cause or by you with Good Reason, whether
or not in connection with a change in control, subject to your execution and delivery of the Separation Agreement and such Separation
Agreement becoming irrevocably effective within 60 days following the termination of your employment (such 60 day
period, the “Release Period”), you will receive (A) continued payment of salary for 12 months; (B) reimbursement
of 12 months of health benefits (COBRA subsidization) in accordance with the Company’s standard expense reimbursement
procedures, (C) if you were still employed by the Company as of the last day of any calendar year but your employment is terminated
before the date of the payment of any Annual Bonus related to such calendar year, the Annual Bonus for such calendar year that otherwise
would have been payable had you remained employed through the payment (the “Post-Termination Bonus”); (D) a pro-rated
portion of your Annual Bonus equal to one hundred percent (100%) of the target level set forth in Section 1 (the target level
is defined as the amount of the Annual Bonus determined by the Company’s Board of Directors (the “Board”) in
good faith based on the level of achievement of the Company’s objectives established by the Board and your personal objectives established
by the CEO with your input) for the calendar year during which the termination of your employment occurs multiplied by a fraction with
the numerator equal to the number of days you worked during such calendar year and the denominator equal to 365 (the “Pro-Rated
Bonus”) and any amount payable with respect to the Post-Termination Bonus or Pro-Rated Bonus shall be paid at the same time
and in the same form as would have been paid had you not been terminated; but not before January 1 or after December 31 of the
year following the year in which your employment terminates (such continued base salary, COBRA subsidization, and pro-rated bonus, collectively,
the “Severance”). For purposes of this Agreement, “Cause” means: (i) your continued and willful
failure to substantially perform the material duties and obligations under this Agreement (for reasons other than death or disability),
which failure, if curable within the discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty
(30) days after receipt of written notice from the Company of such failure; (ii) your willful failure or refusal to comply with
the policies, standards and regulations established by the Company from time to time which failure, if curable in the discretion of the
Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written notice of such
failure from the Company; (iii) any act of personal dishonesty, fraud, embezzlement, misrepresentation, or other unlawful act committed
by you that benefits you at the expense of the Company; (iv) your violation of a federal or state law or regulation applicable to
the Company’s business; (v) your plea of nolo contendere or guilty to, any misdemeanor involving moral turpitude or any felony
under the laws of the United States or any state; (vi) your material breach of the terms of this Agreement or the Confidentiality
Agreement; or (vii) your continued failure to take such lawful actions as directed by the Board which failure, if curable in the
discretion of the Company, is not cured to the reasonable satisfaction of the Company within thirty (30) days after receipt of written
notice of such failure from the Company. For purposes of this Agreement, “Good Reason” means (i) a reduction in
your base salary other than comparable reductions applied to substantially all similarly situated employees, (ii) the relocation
of your principal place of employment by more than fifty (50) miles from the prior location, or (iii) a material diminution
in your title, duties, or responsibilities; provided, however a resignation shall be for Good Reason only if (X) you
provide written notice to the Company of the potential Good Reason trigger within thirty (30) days of the occurrence of the potential
Good Reason trigger, (Y) the Company does not cure the potential Good Reason trigger within thirty (30) days of receipt of notice,
and (Z) you resign your employment within thirty (30) days following the expiration of the Company’s 30-day cure
period. Severance shall accrue until the required Separation Agreement becomes irrevocably effective, with accrued amounts paid on the
first regularly scheduled payroll date thereafter; provided, however, that in the event the Release Period spans two calendar
years, no Severance shall be paid or provided prior to January 1 of the second calendar year. In the case of voluntary resignation
or termination for Cause, you will be subject to a 12 month non-compete in the general area of business or proposed business
of NeuBase (the “Competitive Field”).

 

    3

     

    

 

6.            Arbitration.
You and the Company agree to submit to mandatory binding arbitration any and all claims arising out of or related to your employment with
the Company and the termination thereof, including, but not limited to, claims for unpaid wages, wrongful termination, torts, equity or
phantom equity in the Company, and/or discrimination (including harassment) based upon any federal, state or local ordinance, statute,
regulation or constitutional provision except that each party may, at its or his option, seek injunctive relief in court related to claims
arising under the Confidentiality Agreement or otherwise relating to the improper use, disclosure or misappropriation of a party’s
proprietary, confidential or trade secret information. THE PARTIES HEREBY WAIVE ANY RIGHTS THEY MAY HAVE TO TRIAL BY JURY IN REGARD
TO SUCH CLAIMS. All arbitration hearings shall be conducted in Pittsburgh, Pennsylvania. This letter does not apply or preclude resort
to government agency processes or proceedings, and does not restrict your right to file administrative claims you may bring before any
government agency where, as a matter of law, the parties may not restrict the employee’s ability to file such claims (including,
but not limited to, the National Labor Relations Board, the Equal Employment Opportunity Commission and the Department of Labor). However,
the parties agree that, to the fullest extent permitted by law, arbitration shall be the exclusive remedy for the subject matter of such
administrative claims. The arbitration shall be conducted through JAMS before a single neutral arbitrator, in accordance with the JAMS
employment arbitration rules then in effect, a copy of which can be obtained at https://www.jamsadr.com/rules-employment- arbitration/.
Except as otherwise may be required by law, the parties to the arbitration shall share equally the JAMS fee and the arbitrator’s
fee; provided, however, that the arbitrator at the conclusion of the arbitration shall award costs and fees to the prevailing
party. The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the decision is based.
The Federal Arbitration Act shall govern this section, but if for any reason the FAA is held to be inapplicable, then the law of arbitrability
of Pennsylvania shall apply.

 

    4

     

    

 

7.            Full-Time
Employee. Since you are a full-time employee, during the term of your employment you agree to devote your best efforts to the interests
of the Company and not to engage in employment that competes with or otherwise has an adverse effect on the Company’s business or
your ability to perform your services hereunder. Notwithstanding anything to the contrary contained in this Agreement, (i) you may
engage in religious, charitable or other community activities (ii) you may serve as an advisor to 3rd party companies which
are not in the Competitive Field as long as such services and activities are mutually agreed upon with the CEO and disclosed to the Board
and do not interfere with the performance of your duties to the Company and (iii) you may serve as a member of the Scientific Advisory
Board of Summation Bio, Inc.

 

8.            Electronic
Communication. Company may, in its sole discretion, decide to deliver to you by email or any other electronic means any documents
or notices related to this letter, securities of the Company or any of its affiliates or any other matter, including documents and/or
notices required to be delivered to you by applicable securities law or any other law or Company’s Certificate of Incorporation
or Bylaws. You hereby consent to receive such documents and notices by such electronic delivery (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) and agree
to participate through any on-line or electronic system that may be established and maintained by Company or a third party designated
by Company.

 

9.            Entire
Agreement; Applicable Law. This offer, the Confidentiality Agreement and the Grant Documents, once accepted, constitute the entire
agreement between you and the Company with respect to the subject matter hereof and thereof and supersede all prior offers, negotiations
and agreements, if any, whether written or oral, relating to such subject matter. You acknowledge that neither the Company nor its agents
have made any promise, representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this
letter for the purpose of inducing you to countersign this letter, and you acknowledge that you have countersigned this letter in reliance
only upon such promises, representations and warranties as are contained herein. Except to the extent governed by federal law, this letter
will be construed and enforced according to the laws of the State of Pennsylvania, other than the choice of law provisions thereof.

 

10.            Taxes.
The Company shall withhold taxes and other amounts from payments it makes pursuant to this letter as it reasonably determines.

 

11.            Section 409A.
This Agreement is intended to meet the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”),
and will be interpreted and construed consistent with that intent. For purposes of this Agreement, the terms “terminate,”
 “terminated” and “termination” mean a termination of your employment that constitutes a “separation from
service” within the meaning of the default rules of Section 409A. Notwithstanding any other provision of this Agreement,
to the extent that the right to any payment (including the provision of benefits) hereunder provides for the “deferral of compensation”
under Section 409A, the payment will be paid (or provided) in accordance with the following: if you are a “Specified Employee”
within the meaning of Section 409A on the date of your termination of employment, then no such payment shall be made or commence
during the period beginning on the date of termination and ending on the date that is six (6) months following the date of termination
or, if earlier, on the date of your death. The amount of any payment that would otherwise be paid to you during this period will instead
be paid on the fifteenth (15th) day of the first calendar month following the end of the period. Furthermore, payments
with respect to reimbursements of expenses shall be made on or before the last day of the calendar year following the calendar year in
which the relevant expense is incurred. The amount of expenses eligible for reimbursement during a calendar year may not affect the expenses
eligible for reimbursement in any other calendar year.

 

    5

     

    

 

12.            Validity/Severability.
The invalidity or unenforceability of any provision of this letter shall not affect the validity or enforceability of any other provision
of this letter, which shall remain in full force and effect. If any provision of this letter is determined by any court or arbitrator
of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent
possible given our intent hereto.

 

13.            Acceptance.
If you decide to accept our offer, please countersign the enclosed copy of this letter in the space indicated, as well as the Confidentiality
Agreement and return both documents to me. Your signatures will acknowledge that you have read and understood and agreed to the terms
and conditions of this letter and the Confidentiality Agreement. Should you have anything else that you wish to discuss, please do not
hesitate to call me.

 

14.            Background
Check. Our offer of employment is contingent upon completion of a satisfactory background check (including criminal history) conducted
in accordance with applicable law.

 

[SIGNATURE PAGE FOLLOWS]

 

    6

     

    

 

We look forward to the opportunity to welcome
you to the Company.

 

	 	Very truly yours,
	 	 
	 	Dietrich A. Stephan, Ph.D.
	 	Chief Executive Officer
	 	 
	 	 
	 	/s/ Dietrich Stephan, Ph.D.

 

I have read and understood this letter and hereby
acknowledge, accept and agree to the terms as set forth above and further acknowledge that no other commitments were made to me as part
of my employment offer except as specifically set forth herein.

 

	By: /s/ Sandra Rojas-Caro	 
	Employee Name: Sandra Rojas-Caro, MD	 

 

	Date signed:	5/17/2021	 

 

    7

     

    

 

Exhibit A

 

Employee Proprietary Information and Invention
Assignment Agreement

 

    8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]